By What Percentage Did J&J’s Revenue & EBITDA Grow In The Last 5 Years?

+13.79%
Upside
158
Market
180
Trefis
JNJ: Johnson & Johnson logo
JNJ
Johnson & Johnson

  • 14% Revenue Growth Driven By Immunology & Cancer Drugs
  • 20% EBITDA Growth Driven By Revenue Increase And Margin Expansion

 

J&J_Q3

Relevant Articles
  1. Will Johnson & Johnson Stock Rebound To Its Pre-Inflation Shock Highs of $185?
  2. Should You Pick Johnson & Johnson Stock At $160?
  3. Should You Pick Johnson & Johnson Stock After A 6% Fall In A Month Despite Upbeat Q3?
  4. What’s Happening With Johnson & Johnson Stock?
  5. Johnson & Johnson Poised For A Muted Q2?
  6. Cross-Sector Comparison: Is Caterpillar Stock A Better Pick Over J&J?

Have more questions about Johnson & Johnson? See the links below.

Note: The figures mentioned are approximate values to help our readers remember and grasp the concept more intuitively. For accurate figures, please refer to our complete analysis for Johnson & Johnson

See More at Trefis | View Interactive Institutional Research (Powered by Trefis)

Get Trefis Technology